Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

3 Aug 2020

Abstract excerpt

Abstract Higher tumor mutational burden (TMB) has been correlated with response to checkpoint blockade immunotherapy. However, it is unclear whether TMB independently serves as a prognostic biomarker for outcomes in immunotherapy-naïve patients. Here, we evaluated the relationship between TMB and overall survival in 1,415 immunotherapy-naïve patients with diverse advanced malignancies. TMB was studied both as a...

Source

Identifiers

PMID: 32747422
DOI: 10.1158/1535-7163.mct-20-0161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersPMID 32747422Read ↗

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read ↗

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

High tumor mutational burden predicts survival and responses to ICI immunotherapy in a cancer-dependent mannerSemantic proximity Read ↗

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore.Semantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.Semantic proximity Read ↗

The Impact of TMB on Immunotherapy Protocols: A Comprehensive Analysis of Four Major CancersSemantic proximity Read ↗

Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study.Semantic proximity Read ↗

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

Correlate tumor mutation burden with immune signatures in human cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.